Study | Prové & Varenne (1965) | Van de Voorde et al. (1967-1968) | Waege et al. (1993) | Waege et al. (1993) | Rosiers & Van Hal (2005) | Rosiers & Van Hal (2005) |
---|---|---|---|---|---|---|
Number of respondents | (n = 1,848) | (n = 6,982) | (n = 1,936) | (n = 2,007) | (n = 1,501) | (n = 1,501) |
Male/Female | M: 83.7% F: 16.3% | M: 77.1% F: 22.9% | M: 50.9%/F: 49,1% | M: 46.9%/F: 53.1% | ||
Residential/ commuter | R: 46.3% C: 53.7% | R: 81.4% C: 18.6% | R: 81.6% C: 18.4% | R: 29.0%/C: 71.0% | ||
Reference period | Exams | Last year | Exams | Pre-exams | Exams | Last year |
Prevalence (%) | 5.7% | 5.7% | 9.5% | 3.6% | 2.6% | 2.9% |
Numbers of stimulant users | (n = 106) | (n = 395) | (n = 183) | (n = 73) | (n = 39) | (n = 44) |
Gender: | ns | ns | ns | - | - | ** |
Male (%) | 5.4% | 5.9% | 8.9% | Â | Â | 4.3% |
Female (%) | 7.6% | 4.7% | 10.4% | Â | Â | 1.8% |
Level of significance | p = 0.12 | p = 0.07 | p = 0.27 | - | - | p = 0.004 |
Living status: | ** | * | *** | - | - | * |
Residential (%) | 7.6% | 6.0% | 13.2% | Â | Â | 4.7% |
Commuter (%) | 4.1% | 4.3% | 5.6% | Â | Â | 2.4% |
Level of significance | p = 0.001 | p = 0.04 | p < 0.001 | - | - | p = 0.04 |
Most popular products | Rilatine® (38.7%) | Rilatine® (35.4%) | Catovit®(80%) Captagon® (14%) | - |